[go: up one dir, main page]

SG11202009877XA - Oligonucleotide compositions and methods of use thereof - Google Patents

Oligonucleotide compositions and methods of use thereof

Info

Publication number
SG11202009877XA
SG11202009877XA SG11202009877XA SG11202009877XA SG11202009877XA SG 11202009877X A SG11202009877X A SG 11202009877XA SG 11202009877X A SG11202009877X A SG 11202009877XA SG 11202009877X A SG11202009877X A SG 11202009877XA SG 11202009877X A SG11202009877X A SG 11202009877XA
Authority
SG
Singapore
Prior art keywords
methods
oligonucleotide compositions
oligonucleotide
compositions
Prior art date
Application number
SG11202009877XA
Inventor
Jason Jingxin Zhang
Chandra Vargeese
Naoki Iwamoto
Chikdu Shakti Shivalila
Nayantara Kothari
Ann Fiegen Durbin
Selvi Ramasamy
Pachamuthu Kandasamy
Jayakanthan Kumarasamy
Gopal Reddy Bommineni
Subramanian Marappan
Sethumadhavan Divakaramenon
David Charles Donnell Butler
Genliang Lu
Hailin Yang
Mamoru Shimizu
Prashant Monian
Original Assignee
Wave Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wave Life Sciences Ltd filed Critical Wave Life Sciences Ltd
Publication of SG11202009877XA publication Critical patent/SG11202009877XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/02Phosphorylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/09Pyrimidine radicals with arabinosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/312Phosphonates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/33Alteration of splicing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/30Production chemically synthesised

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202009877XA 2018-04-12 2019-04-11 Oligonucleotide compositions and methods of use thereof SG11202009877XA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862656949P 2018-04-12 2018-04-12
US201862670709P 2018-05-11 2018-05-11
US201862715684P 2018-08-07 2018-08-07
US201862723375P 2018-08-27 2018-08-27
US201862776432P 2018-12-06 2018-12-06
PCT/US2019/027109 WO2019200185A1 (en) 2018-04-12 2019-04-11 Oligonucleotide compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202009877XA true SG11202009877XA (en) 2020-11-27

Family

ID=68163789

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009877XA SG11202009877XA (en) 2018-04-12 2019-04-11 Oligonucleotide compositions and methods of use thereof

Country Status (12)

Country Link
US (1) US20220306573A1 (en)
EP (1) EP3775203A4 (en)
JP (2) JP2021521140A (en)
KR (1) KR20210005057A (en)
CN (1) CN112004928A (en)
AU (1) AU2019252680B2 (en)
BR (1) BR112020020670A2 (en)
CA (1) CA3096667A1 (en)
IL (2) IL277889B2 (en)
MX (1) MX2020010687A (en)
SG (1) SG11202009877XA (en)
WO (1) WO2019200185A1 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2872485T3 (en) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymmetric auxiliary group
CN104661664B (en) 2012-07-13 2020-07-03 波涛生命科学有限公司 Chiral control
EP4137572A1 (en) 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design
RU2708237C2 (en) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Modified oligonucleotides and method for production thereof
MA43072A (en) 2015-07-22 2018-05-30 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
MA43822A (en) 2016-03-13 2018-11-28 Wave Life Sciences Ltd COMPOSITIONS AND SYNTHESIS OF PHOSPHORAMIDITE AND OLIGONUCLEOTIDES
WO2017210647A1 (en) 2016-06-03 2017-12-07 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
DK3507366T3 (en) 2016-09-01 2020-11-02 Proqr Therapeutics Ii Bv CHEMICAL MODIFIED, SINGLE STRANDED RNA-MODIFYING OLIGONUCLEOTIDES
MA46905A (en) 2016-11-23 2019-10-02 Wave Life Sciences Ltd COMPOSITIONS AND SYNTHESIS OF PHOSPHORAMIDITES AND OLIGONUCLEOTIDES
CN120249271A (en) 2017-06-02 2025-07-04 波涛生命科学有限公司 Oligonucleotide compositions and methods of use thereof
WO2018223056A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
EP3642182A4 (en) 2017-06-21 2020-12-09 Wave Life Sciences Ltd. COMPOUNDS, COMPOSITIONS AND METHODS OF SYNTHESIS
CN111032057A (en) 2017-08-08 2020-04-17 波涛生命科学有限公司 Oligonucleotide compositions and methods thereof
US11608355B2 (en) 2017-09-18 2023-03-21 Wave Life Sciences Ltd. Technologies for oligonucleotide preparation
JP2020537518A (en) 2017-10-12 2020-12-24 ウェーブ ライフ サイエンシーズ リミテッド Oligonucleotide composition and its method
TWI844541B (en) 2018-05-11 2024-06-11 新加坡商波濤生命科學有限公司 Oligonucleotide compositions and methods of use thereof
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
SG11202100934PA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20230089442A1 (en) * 2019-03-20 2023-03-23 Pachamuthu Kandasamy Technologies useful for oligonucleotide preparation
US12497615B2 (en) 2019-04-25 2025-12-16 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
CN114555621B (en) 2019-08-15 2025-10-28 Ionis制药公司 Bond-modified oligomeric compounds and uses thereof
JP2023506540A (en) * 2019-12-19 2023-02-16 エフ. ホフマン-ラ ロシュ エージー. Use of SCAMP3 inhibitors to treat hepatitis B virus infection
BR112022012114A2 (en) * 2019-12-19 2022-09-06 Nippon Shinyaku Co Ltd ANTISENSE NUCLEIC ACID THAT ALLOWS THE LEAP OF EXONS
MX2022014606A (en) * 2020-05-22 2023-03-08 Wave Life Sciences Ltd Double stranded oligonucleotide compositions and methods relating thereto.
EP4153604A4 (en) * 2020-05-22 2024-11-27 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREFOR
CN112063621B (en) * 2020-09-02 2022-06-28 西湖大学 Duchenne muscular dystrophy-related exon splicing enhancers, sgRNAs, gene editing tools and their applications
CN112430645A (en) * 2020-12-09 2021-03-02 北京华瑞康源生物科技发展有限公司 Relative quantitative method and kit for detecting human DMD gene copy number by multiple real-time fluorescence PCR method
CN118852286A (en) * 2021-01-14 2024-10-29 施能康生物科技有限公司 Compounds, conjugates and uses thereof
IL309626A (en) 2021-06-23 2024-02-01 Nippon Shinyaku Co Ltd Combination of antisense oligomers
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2022309028A1 (en) 2021-07-09 2024-01-25 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
WO2023006985A1 (en) * 2021-07-30 2023-02-02 4Basebio Uk Ltd Nanoparticles and peptides for the delivery of cargos to muscle cells
EP4124345A1 (en) * 2021-07-30 2023-02-01 4basebio UK Ltd Nanoparticles for muscle delivery
CA3227661A1 (en) * 2021-08-05 2023-02-09 Weimin Wang 1'-alkyl modified ribose derivatives and methods of use
US20250154504A1 (en) 2022-02-14 2025-05-15 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
AU2023227808A1 (en) * 2022-03-02 2024-09-19 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof for exon skipping
CN114600803B (en) * 2022-03-15 2023-05-09 北京协和建昊医药技术开发有限责任公司 Zebra fish CYP3A4 metabolic enzyme inhibition model, establishing method and application
IL317425A (en) * 2022-06-10 2025-02-01 Camp4 Therapeutics Corp Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
JP2025524566A (en) 2022-07-15 2025-07-30 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ Oligonucleotides for ADAR-mediated RNA editing and uses thereof
WO2024013360A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024110565A1 (en) 2022-11-24 2024-05-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
EP4630553A1 (en) 2022-12-09 2025-10-15 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
EP4669753A1 (en) 2023-02-20 2025-12-31 ProQR Therapeutics II B.V. ANTISENSEE OLIGONUCLEOLITES FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
CN121039282A (en) 2023-03-24 2025-11-28 ProQR治疗上市公司Ⅱ Antisense oligonucleotides for the treatment of neurological disorders
WO2024200472A1 (en) 2023-03-27 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
AR132964A1 (en) 2023-06-16 2025-08-13 Proqr Therapeutics Ii Bv ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
AU2024287308A1 (en) 2023-07-13 2025-12-18 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
WO2025051946A1 (en) 2023-09-07 2025-03-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2025056973A2 (en) * 2023-09-13 2025-03-20 Haya Therapeutics Sa Compositions and methods for modulating wisp2 super-enhancer-associated rna
WO2025072886A1 (en) * 2023-09-28 2025-04-03 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2025072883A2 (en) * 2023-09-28 2025-04-03 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
AU2024369609A1 (en) 2023-10-31 2025-12-11 Korro Bio, Inc. Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025104239A1 (en) 2023-11-16 2025-05-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
WO2025132708A1 (en) 2023-12-20 2025-06-26 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
WO2025199428A1 (en) * 2024-03-21 2025-09-25 Adarx Pharmaceuticals, Inc. Mannose receptor ligand-tropomyosin receptor b ligand conjugates for drug delivery
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852188A (en) * 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
DK0464638T3 (en) * 1990-07-02 1997-10-13 Hoechst Ag Oligonucleotide analogs with terminal 3-3 or 5-5 internucleotide bonds.
US5512668A (en) * 1991-03-06 1996-04-30 Polish Academy Of Sciences Solid phase oligonucleotide synthesis using phospholane intermediates
US6242589B1 (en) * 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
AR040996A1 (en) * 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
SI1766010T1 (en) * 2004-06-28 2011-06-30 Univ Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
JP2006248949A (en) * 2005-03-09 2006-09-21 Univ Nagoya Nucleoside derivatives, nucleotide derivatives and methods for producing them
ATE443072T1 (en) * 2005-11-23 2009-10-15 Roche Diagnostics Gmbh POLYNUCLEOTIDE WITH PHOSPHATE MIMETIC
PL2203173T3 (en) * 2007-10-26 2016-06-30 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2370451B1 (en) * 2008-12-02 2016-11-16 Wave Life Sciences Japan, Inc. Method for the synthesis of phosphorus atom modified nucleic acids
CA2877644A1 (en) * 2012-07-03 2014-01-09 Prosensa Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
CN104661664B (en) * 2012-07-13 2020-07-03 波涛生命科学有限公司 Chiral control
CA2879066C (en) * 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
PL2872485T3 (en) * 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymmetric auxiliary group
EP4137572A1 (en) * 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design
RU2708237C2 (en) * 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Modified oligonucleotides and method for production thereof
MA43072A (en) * 2015-07-22 2018-05-30 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
KR20180056766A (en) * 2015-10-09 2018-05-29 웨이브 라이프 사이언시스 리미티드 Nucleotide compositions and methods thereof
WO2017210647A1 (en) * 2016-06-03 2017-12-07 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof

Also Published As

Publication number Publication date
MX2020010687A (en) 2021-01-20
IL277889A (en) 2020-11-30
KR20210005057A (en) 2021-01-13
IL277889B2 (en) 2025-01-01
US20220306573A1 (en) 2022-09-29
EP3775203A1 (en) 2021-02-17
CN112004928A (en) 2020-11-27
WO2019200185A1 (en) 2019-10-17
IL277889B1 (en) 2024-09-01
AU2019252680A1 (en) 2020-10-22
JP2021521140A (en) 2021-08-26
IL314987A (en) 2024-10-01
EP3775203A4 (en) 2022-03-30
BR112020020670A2 (en) 2021-03-02
AU2019252680B2 (en) 2025-11-06
CA3096667A1 (en) 2019-10-17
JP2023139036A (en) 2023-10-03

Similar Documents

Publication Publication Date Title
IL277889A (en) Oligonucleotide compositions and methods of use thereof
SG11202010131QA (en) Oligonucleotide compositions and methods of use thereof
SG11202111387YA (en) Oligonucleotide compositions and methods of use thereof
SG11202111386UA (en) Oligonucleotide compositions and methods of use thereof
IL274276A (en) Casz compositions and methods of use
SG11202105626TA (en) Oligonucleotide compositions and methods thereof
IL284882A (en) Oligonucleotide compositions and methods thereof
GB2582100B (en) CAS12C Compositions and methods of use
ZA202007839B (en) Polymerases, compositions, and methods of use
ZA202007838B (en) Polymerases, compositions, and methods of use
EP3965780A4 (en) Oligonucleotide compositions and methods of use thereof
SG11202001783YA (en) Oligonucleotide compositions and methods thereof
ZA201906169B (en) Synthekine compositions and methods of use
IL276135A (en) Compositions and methods of use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
GB202105087D0 (en) Microbial compositions and methods of use
IL282533A (en) Oligosaccharide compositions and methods of use thereof
ZA202000502B (en) Cosmetic compositions and methods of use
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
ZA201908276B (en) Charge-tagged nucleotides and methods of use thereof
IL274433A (en) Fulvestrant formulations and methods of their use
IL277801A (en) Oxytocin compositions and methods of use
IL261794A (en) Compositions and methods of their use
ZA202007107B (en) Compositions comprising pcsk9-binding molecules and methods of use
HK40079904A (en) Oligonucleotide compositions and methods of use thereof